DXS (UK) LIMITED

• ·

  Negative shareholders' funds

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Crowe U.K. LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”

Significant events

• “While continued changes to government and NHS funding programmes have continued to influence the company's pace of growth, DXS has remained focussed on delivering outstanding service, advancing our innovative healthcare solutions and building new relationships across the NHS.”
• “GPIT Futures was originally meant to be renewed by March 2023, was delayed until March 2024, then delayed again, and has now committed to being in place by 1 April 2026.”
• “The principal risk to the company is that the NHS dramatically changes its plans or cuts its budgets. However, this seems unlikely particularly with the current staffing levels highlighting the need for clinicians to operate using digital technologies.”
• “The company continues to invest in research and development both locally and internationally and during this financial year has invested £705,292 into R&D for the introduction, continuation, and completion of a number of new DXS solutions.”
• “As per the NHS mandate requiring NHS accredited suppliers to continue a process of innovation, the company has invested heavily into developing new innovative solutions to meet the NHS unmet needs. However, while there is no doubt as to the potential benefits to be realised for the NHS, the slow pace at which the NHS has been, and continues to operate is frustrating.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.